This programme has received an educational grant from A. Menarini Farmaceutica Internazionale Srl [AMFI]. Any comments or opinions expressed by the authors are independent of any editorial input from AMFI and do not necessarily reflect the views of AMFI.
NEW ANTIANGINAL AGENTS – FOCUS ON RANOLAZINE
Disclaimer
Scientific programme prepared by
The Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, UK.
Objectives
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Programme coordinator
Prof Juan Carlos Kaski
Professor of Cardiovascular Science, Cardiovascular and Cell Sciences Research Institute,St George’s, University of London, UK
Content
Cardio Notes
Brief summaries of specific topics related to the use of anti-angina agents and practical comments by experts
- Guidelines (ESC & NICE) for the pharmacological management of angina pectoris - What's new?
- Pharmacological treatment of stable angina - Conventional and novel anti-anginal agents
- Ranexa - Mode of action, dosing and side effects
- Ranolazine: indications, adverse reactions and contraindications
- Use of ranolazine in chronic stable angina patients and patients with type 2 diabetes mellitus - Summary of CARISA, MARISA & TERISA trials
- Concomitant use of ranolazine and conventional anti-anginal agents
Cardio Interviews
Face to face discussions on the management of angina pectoris and the use of ranolazine in clinical practice
Expert opinions by
